Hudson, M. P., Granger, C. B., O’Neill, W. W., Stebbins, A. L., Widimsky, P., Aylward, P., … Armstrong, P. W. (2007). Faster times to primary percutaneous coronary intervention are associated with better survival: Insights from the APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infraction) trial. In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (Vol. 49, pp. 42B-43B). New Orleans, LA: ELSEVIER SCIENCE INC.

Hudson, Michael P., Christopher B. Granger, William W. O’Neill, Amanda L. Stebbins, Petr Widimsky, Phillip Aylward, Witold Ruzyllo, David Holmes, Kenneth W. Mahaffey, and Paul W. Armstrong. “Faster times to primary percutaneous coronary intervention are associated with better survival: Insights from the APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infraction) trial.” In JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 49:42B-43B. ELSEVIER SCIENCE INC, 2007.

Hudson MP, Granger CB, O’Neill WW, Stebbins AL, Widimsky P, Aylward P, et al. Faster times to primary percutaneous coronary intervention are associated with better survival: Insights from the APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infraction) trial. In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC; 2007. p. 42B-43B.

Hudson, Michael P., et al. “Faster times to primary percutaneous coronary intervention are associated with better survival: Insights from the APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infraction) trial.” JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 49, no. 9, ELSEVIER SCIENCE INC, 2007, pp. 42B-43B.

Hudson MP, Granger CB, O’Neill WW, Stebbins AL, Widimsky P, Aylward P, Ruzyllo W, Holmes D, Mahaffey KW, Armstrong PW. Faster times to primary percutaneous coronary intervention are associated with better survival: Insights from the APEX-AMI (Assessment of Pexelizumab in Acute Myocardial Infraction) trial. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. ELSEVIER SCIENCE INC; 2007. p. 42B-43B.